Status:
COMPLETED
Real-world Data on Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy in Asia Area (PACIFIC AA)
Lead Sponsor:
AstraZeneca
Conditions:
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
Brief Summary
First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy in Asia Area
Detailed Description
Study Design: The study is an observational review of medical records of patients diagnosed with unresectable stage III NSCLC in Taiwan, participating in an early access program (EAP). Physicians havi...
Eligibility Criteria
Inclusion
- Written informed consent or any locally required authorisation obtained from the patient prior to performing any protocol-related procedures
- Adult of age ≥ 20 years at time of study entry
- Patients must have been enrolled in one of the Pacific durvalumab EAPs
Exclusion
- 1\. Patients treated with durvalumab in clinical studies prior to the index date (first dose of durvalumab received within the EAP).
Key Trial Info
Start Date :
June 12 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 29 2023
Estimated Enrollment :
106 Patients enrolled
Trial Details
Trial ID
NCT04529564
Start Date
June 12 2020
End Date
June 29 2023
Last Update
August 13 2024
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital-Hsinchu Branch
Hsinchu, Taiwan
2
Chang Gung Medical Foundation-Kaohsiung Branch
Kaohsiung City, Taiwan
3
Chang Gung Medical Foundation-Keelung Branch
Keelung, Taiwan
4
China Medical University Hospital
Taichung, Taiwan